37
Background:
Broad genomic profiling (BGP) is increasingly used in metastatic non-small cell lung cancer (mNSCLC), but its association with downstream treatment-related Medicare spending compared to focused gene testing (FGT) remains unclear.
Methods:
We conducted a retrospective cohort study using SEER-Med...
Akintunde O. Aremu, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
209
Background:
Patients with non-small cell lung cancer (NSCLC) living in rural areas face numerous barriers to care. Although rural-urban disparities in lung cancer care are well documented, less is known about variation in treatment and survival across rural and urban counties or how these patterns have chan...
Tanvee Varma, Do Lee, P. Soulos et al.· JCO Oncology Practice· 0 citations
40
Background:
The use of biologic therapy for patients with mCRC is incompletely characterized. We evaluated receipt of biomarker matched guideline concordant treatment with VEGF inhibitors (VEGFi), EGFR antibodies (EGFRa), and immune checkpoint inhibitors (ICI), assessing treatment by sociodemographic, clinic...
T. Salah, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.